Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows from operating activities:
Net income	$ 26,060	$ 17,228
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	3,806	3,878
Bad debt provision	3,784	1,088
Deferred income taxes	607	(1,473)
Share-based compensation expense	2,764	3,738
Amortization of premium on marketable securities	48	117
Unrealized loss on deferred compensation fund investments	1,583	1,448
Changes in other long-term liabilities	0	9
Net loss on disposals of property and equipment	91	113
Share of losses from equity method investment	0	(43)
Changes in operating assets and liabilities:
Accounts and notes receivable	(15,166)	2,241
Inventories and supplies	906	(525)
Prepaid expenses and other assets	(7,800)	(4,053)
Deferred compensation funding	1,545	976
Accounts payable and other accrued expenses	4,490	(5,512)
Accrued payroll, accrued and withheld payroll taxes	20,319	(4,591)
Deferred ERC credits	0	12,157
Income taxes receivable	8,018	1,212
Accrued insurance claims	(4,210)	2,174
Deferred compensation liability	(3,115)	(2,681)
Net cash from operating activities	43,730	27,501
Cash flows from investing activities:
Disposals of property and equipment	55	26
Additions to property and equipment	(1,398)	(1,743)
Cash paid for acquisition	0	(7,287)
Cash paid for investments	(4,575)	(2,125)
Purchases of marketable securities	(7,313)	(3,436)
Sales of marketable securities	1,682	95
Net cash from investing activities	(11,549)	(14,470)
Cash flows from financing activities:
Purchases of treasury stock	(23,964)	(7,036)
Payments of statutory withholding on net issuance of restricted stock units	(4,162)	(1,744)
Proceeds from the exercise of stock options	1,448	0
Net cash from financing activities	(26,678)	(8,780)
Net increase in cash, cash equivalents and restricted cash equivalents	5,503	4,251
Cash, cash equivalents and restricted cash equivalents at beginning of the period	130,766	60,131
Cash, cash equivalents and restricted cash equivalents at end of the period	$ 136,269	$ 64,382